Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Measurement of prostate specific antigen

INTRODUCTION

Prostate specific antigen (PSA) is a glycoprotein that is expressed by both normal and neoplastic prostate tissue. PSA is consistently expressed in nearly all prostate cancers, although its level of expression on a per cell basis, especially in very poorly differentiated prostate cancers, is lower than in normal prostate epithelium. The absolute value of serum PSA is useful for determining the extent of prostate cancer and assessing the response to prostate cancer treatment; its use as a screening method to detect prostate cancer is also common, although controversial. (See "Clinical presentation and diagnosis of prostate cancer" and "Screening for prostate cancer".)

The measurement of PSA, causes of abnormal values, and advances in PSA testing will be reviewed here. Recommendations for the clinical use of PSA testing in screening for prostate cancer are presented separately. (See "Screening for prostate cancer".)

PSA EXPRESSION AND PROCESSING

Under normal conditions, PSA is produced as a proenzyme (proPSA) by the secretory cells that line the prostate glands (acini) and secreted into the lumen, where the propeptide is removed to generate active PSA. The active PSA can then undergo proteolysis to generate inactive PSA, of which a small portion then enters the bloodstream and circulates in an unbound state (free PSA). Alternatively, active PSA can diffuse directly into the circulation where it is rapidly bound by protease inhibitors, including alpha-1-antichymotrypsin (ACT) and alpha-2-macroglobulin [1,2].

Although generating less PSA per cell than normal tissue, prostate cancer lacks basal cells, resulting in the disruption of the basement membrane and normal lumen architecture. As a result, the secreted proPSA and several truncated forms have direct access to the circulation resulting in more PSA “leaked” into the blood and a larger fraction of the PSA produced by malignant tissue escapes proteolytic processing (ie, activation of proPSA to active PSA and degradation of active PSA to inactive PSA).

In men with a normal prostate (ie, no cancer and no major inflammation/infection), the majority of free PSA in the serum reflects the mature protein that has been inactivated by internal proteolytic cleavage. In contrast, this cleaved fraction is relatively decreased in prostate cancer. Thus, the percentage of free or unbound PSA is lower in the serum of men with prostate cancer (and conversely, the amount of complexed PSA is higher) compared with those who have a normal prostate or BPH [3-6]. This finding has been exploited in the use of the ratio of free to total PSA and complexed PSA (cPSA) as a means of distinguishing between prostate cancer and BPH as a cause of an elevated PSA. (See 'Serum free and bound PSA' below and 'Complexed PSA' below.)

                    

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jun 2014. | This topic last updated: Nov 22, 2013.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Lilja H, Christensson A, Dahlén U, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991; 37:1618.
  2. Mikolajczyk SD, Marks LS, Partin AW, Rittenhouse HG. Free prostate-specific antigen in serum is becoming more complex. Urology 2002; 59:797.
  3. Björk T, Piironen T, Pettersson K, et al. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer. Urology 1996; 48:882.
  4. Christensson A, Björk T, Nilsson O, et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993; 150:100.
  5. Partin AW, Hanks GE, Klein EA, et al. Prostate-specific antigen as a marker of disease activity in prostate cancer. Oncology (Williston Park) 2002; 16:1024.
  6. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003; 21:383.
  7. Coley CM, Barry MJ, Fleming C, Mulley AG. Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The American College of Physicians. Ann Intern Med 1997; 126:394.
  8. Link RE, Shariat SF, Nguyen CV, et al. Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening. J Urol 2004; 171:2234.
  9. Crawford ED. Prostate Cancer Awareness Week: September 22 to 28, 1997. CA Cancer J Clin 1997; 47:288.
  10. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993; 270:860.
  11. Morgan TO, Jacobsen SJ, McCarthy WF, et al. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 1996; 335:304.
  12. Baillargeon J, Pollock BH, Kristal AR, et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer 2005; 103:1092.
  13. Werny DM, Thompson T, Saraiya M, et al. Obesity is negatively associated with prostate-specific antigen in U.S. men, 2001-2004. Cancer Epidemiol Biomarkers Prev 2007; 16:70.
  14. Rundle A, Neugut AI. Obesity and screening PSA levels among men undergoing an annual physical exam. Prostate 2008; 68:373.
  15. Beebe-Dimmer JL, Faerber GJ, Morgenstern H, et al. Body composition and serum prostate-specific antigen: review and findings from Flint Men's Health Study. Urology 2008; 71:554.
  16. Bañez LL, Hamilton RJ, Partin AW, et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007; 298:2275.
  17. Wang LG, Liu XM, Kreis W, Budman DR. Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells. Cancer Res 1997; 57:714.
  18. Guess HA, Gormley GJ, Stoner E, Oesterling JE. The effect of finasteride on prostate specific antigen: review of available data. J Urol 1996; 155:3.
  19. D'Amico AV, Roehrborn CG. Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncol 2007; 8:21.
  20. Etzioni RD, Howlader N, Shaw PA, et al. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol 2005; 174:877.
  21. Andriole GL, Bostwick D, Brawley OW, et al. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol 2011; 185:126.
  22. Marberger M, Freedland SJ, Andriole GL, et al. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int 2012; 109:1162.
  23. Singer EA, Palapattu GS, van Wijngaarden E. Prostate-specific antigen levels in relation to consumption of nonsteroidal anti-inflammatory drugs and acetaminophen: results from the 2001-2002 National Health and Nutrition Examination Survey. Cancer 2008; 113:2053.
  24. Chang SL, Harshman LC, Presti JC Jr. Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey. J Clin Oncol 2010; 28:3951.
  25. Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ. The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst 2008; 100:1511.
  26. Mondul AM, Selvin E, De Marzo AM, et al. Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001-2004. Cancer Causes Control 2010; 21:671.
  27. Bruun L, Becker C, Hugosson J, et al. Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden. Prostate 2005; 65:216.
  28. Nadler RB, Humphrey PA, Smith DS, et al. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995; 154:407.
  29. Sershon PD, Barry MJ, Oesterling JE. Serum prostate-specific antigen discriminates weakly between men with benign prostatic hyperplasia and patients with organ-confined prostate cancer. Eur Urol 1994; 25:281.
  30. Partin AW, Carter HB, Chan DW, et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990; 143:747.
  31. Lange PH, Ercole CJ, Lightner DJ, et al. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 1989; 141:873.
  32. Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 1989; 142:1011.
  33. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997; 277:1452.
  34. Freedland SJ, Aronson WJ, Kane CJ, et al. Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels. Cancer 2004; 101:748.
  35. Dalton DL. Elevated serum prostate-specific antigen due to acute bacterial prostatitis. Urology 1989; 33:465.
  36. Tchetgen MB, Oesterling JE. The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. Urol Clin North Am 1997; 24:283.
  37. Kawakami J, Siemens DR, Nickel JC. Prostatitis and prostate cancer: implications for prostate cancer screening. Urology 2004; 64:1075.
  38. Simardi LH, Tobias-MacHado M, Kappaz GT, et al. Influence of asymptomatic histologic prostatitis on serum prostate-specific antigen: a prospective study. Urology 2004; 64:1098.
  39. Hara N, Koike H, Ogino S, et al. Application of serum PSA to identify acute bacterial prostatitis in patients with fever of unknown origin or symptoms of acute pyelonephritis. Prostate 2004; 60:282.
  40. Ugurlu O, Yaris M, Oztekin CV, et al. Impacts of antibiotic and anti-inflammatory therapies on serum prostate-specific antigen levels in the presence of prostatic inflammation: a prospective randomized controlled trial. Urol Int 2010; 84:185.
  41. Ornstein DK, Smith DS, Humphrey PA, Catalona WJ. The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer. J Urol 1998; 159:1234.
  42. Jung K, Meyer A, Lein M, et al. Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate. J Urol 1998; 159:1595.
  43. Crawford ED, Schutz MJ, Clejan S, et al. The effect of digital rectal examination on prostate-specific antigen levels. JAMA 1992; 267:2227.
  44. Tarhan F, Orçun A, Küçükercan I, et al. Effect of prostatic massage on serum complexed prostate-specific antigen levels. Urology 2005; 66:1234.
  45. Oesterling JE, Rice DC, Glenski WJ, Bergstralh EJ. Effect of cystoscopy, prostate biopsy, and transurethral resection of prostate on serum prostate-specific antigen concentration. Urology 1993; 42:276.
  46. Crawford ED 3rd, Mackenzie SH, Safford HR, Capriola M. The effect of bicycle riding on serum prostate specific antigen levels. J Urol 1996; 156:103.
  47. Luboldt HJ, Peck KD, Oberpenning F, et al. Bicycle riding has no important impact on total and free prostate-specific antigen serum levels in older men. Urology 2003; 61:1177.
  48. Saka T, Sofikerim M, Demirtas A, et al. Rigorous bicycling does not increase serum levels of total and free prostate-specific antigen (PSA), the free/total PSA ratio, gonadotropin levels, or uroflowmetric parameters. Urology 2009; 74:1325.
  49. Tchetgen MB, Song JT, Strawderman M, et al. Ejaculation increases the serum prostate-specific antigen concentration. Urology 1996; 47:511.
  50. Black MH, Giai M, Ponzone R, et al. Serum total and free prostate-specific antigen for breast cancer diagnosis in women. Clin Cancer Res 2000; 6:467.
  51. Alanen KA, Kuopio T, Collan YU, et al. Immunohistochemical labelling for prostate-specific antigen in breast carcinomas. Breast Cancer Res Treat 1999; 56:169.
  52. Diamandis EP. Prostate specific antigen--new applications in breast and other cancers. Anticancer Res 1996; 16:3983.
  53. Benson MC, Whang IS, Olsson CA, et al. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992; 147:817.
  54. Andriole GL, Telle WB, Coplen DE, Catalona WJ. PSA index (PSAI) as a predictor of prostate cancer in men with persistent serum PSA elevation (abstract). J Urol 1992; 147:387A.
  55. Benson MC, Whang IS, Pantuck A, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992; 147:815.
  56. Bare R, Hart L, McCullough DL. Correlation of prostate-specific antigen and prostate-specific antigen density with outcome of prostate biopsy. Urology 1994; 43:191.
  57. Catalona WJ, Richie JP, deKernion JB, et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994; 152:2031.
  58. Stephan C, Stroebel G, Heinau M, et al. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL. Cancer 2005; 104:993.
  59. Brawer MK, Aramburu EA, Chen GL, et al. The inability of prostate specific antigen index to enhance the predictive the value of prostate specific antigen in the diagnosis of prostatic carcinoma. J Urol 1993; 150:369.
  60. Smith DS, Catalona WJ. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 1994; 152:1163.
  61. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267:2215.
  62. Carter HB, Ferrucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006; 98:1521.
  63. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351:125.
  64. D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005; 294:440.
  65. Eggener SE, Yossepowitch O, Roehl KA, et al. Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program. Urology 2008; 71:1016.
  66. Riehmann M, Rhodes PR, Cook TD, et al. Analysis of variation in prostate-specific antigen values. Urology 1993; 42:390.
  67. Fang J, Metter EJ, Landis P, Carter HB. PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml. Urology 2002; 59:889.
  68. Loeb S, Roehl KA, Nadler RB, et al. Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml. J Urol 2007; 178:2348.
  69. Roobol MJ, Kranse R, de Koning HJ, Schröder FH. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). Urology 2004; 63:309.
  70. Raaijmakers R, Wildhagen MF, Ito K, et al. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Urology 2004; 63:316.
  71. Vickers AJ, Savage C, O'Brien MF, Lilja H. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009; 27:398.
  72. Vickers AJ, Till C, Tangen CM, et al. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst 2011; 103:462.
  73. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279:1542.
  74. Hoffman RM, Clanon DL, Littenberg B, et al. Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levels. J Gen Intern Med 2000; 15:739.
  75. Lee R, Localio AR, Armstrong K, et al. A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology 2006; 67:762.
  76. Carter HB, Partin AW, Luderer AA, et al. Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology 1997; 49:379.
  77. Allard WJ, Zhou Z, Yeung KK. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin Chem 1998; 44:1216.
  78. Chichibu K, Kuroe K, Hashimoto C, Goto S. [Specific quantification of gamma-seminoprotein-alpha 1 antichymotrypsin complex in serum by monoclonal antibody-based enzyme immunoassay]. Rinsho Byori 1995; 43:1153.
  79. Kuriyama M, Ueno K, Uno H, et al. Clinical evaluation of serum prostate-specific antigen-alpha1-antichymotrypsin complex values in diagnosis of prostate cancer: a cooperative study. Int J Urol 1998; 5:48.
  80. Brawer MK, Meyer GE, Letran JL, et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 1998; 52:372.
  81. Brawer MK, Cheli CD, Neaman IE, et al. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 2000; 163:1476.
  82. Mitchell ID, Croal BL, Dickie A, et al. A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer. J Urol 2001; 165:1549.
  83. Miller MC, O'Dowd GJ, Partin AW, Veltri RW. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics. Urology 2001; 57:1105.
  84. Okihara K, Fritsche HA, Ayala A, et al. Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng./ml. J Urol 2001; 165:1930.
  85. Partin AW, Brawer MK, Bartsch G, et al. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol 2003; 170:1787.
  86. Horninger W, Cheli CD, Babaian RJ, et al. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. Urology 2002; 60:31.
  87. Stamey TA, Yemoto CE. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume. J Urol 2000; 163:119.
  88. Okihara K, Cheli CD, Partin AW, et al. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol 2002; 167:2017.
  89. Tanguay S, Bégin LR, Elhilali MM, et al. Comparative evaluation of total PSA, free/total PSA, and complexed PSA in prostate cancer detection. Urology 2002; 59:261.
  90. Bratslavsky G, Fisher HA, Kaufman RP Jr, et al. PSA-related markers in the detection of prostate cancer and high-grade disease in the contemporary era with extended biopsy. Urol Oncol 2008; 26:166.
  91. Lein M, Kwiatkowski M, Semjonow A, et al. A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. J Urol 2003; 170:1175.
  92. Allard WJ, Cheli CD, Morris DL, et al. Multicenter evaluation of the performance and clinical utility in longitudinal monitoring of the Bayer Immuno 1 complexed PSA assay. Int J Biol Markers 1999; 14:73.
  93. Sokoll LJ, Sanda MG, Feng Z, et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 2010; 19:1193.